These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37318031)

  • 21. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
    Almquist DR; Ahn DH; Bekaii-Saab TS
    BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinctive genomic characteristics in
    He J; Ouyang W; Zhao W; Shao L; Li B; Liu B; Wang D; Han-Zhang H; Zhang Z; Shao L; Li W
    Ann Transl Med; 2021 Jan; 9(2):129. PubMed ID: 33569431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy.
    Roth MT; Das S
    Expert Rev Anticancer Ther; 2021 Feb; 21(2):229-238. PubMed ID: 33183114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
    Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
    Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
    Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
    Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer.
    El Hajj J; Reddy S; Verma N; Huang EH; Kazmi SM
    J Gastrointest Cancer; 2023 Dec; 54(4):1017-1030. PubMed ID: 37009977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment.
    Saller J; Qin D; Felder S; Coppola D
    Clin Colorectal Cancer; 2020 Jun; 19(2):123-131. PubMed ID: 32171644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete response of metastatic microsatellite-stable
    Ree AH; Høye E; Esbensen Y; Beitnes AR; Negård A; Bernklev L; Tetlie LK; Fretland ÅA; Hamre HM; Kersten C; Hofsli E; Guren MG; Sorbye H; Nilsen HL; Flatmark K; Meltzer S
    Oncoimmunology; 2024; 13(1):2372886. PubMed ID: 38952672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application of immune combination therapy in MSS/pMMR-type colorectal cancer: current status and future perspectives].
    Zhang XL; Fan WX; Du YY; Zhang Y; Su F; Hu WQ; Zhao J
    Zhonghua Zhong Liu Za Zhi; 2024 Aug; 46(8):725-736. PubMed ID: 39143795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
    Hamid MA; Pammer LM; Lentner TK; Doleschal B; Gruber R; Kocher F; Gasser E; Jöbstl A; Seeber A; Amann A
    Curr Oncol Rep; 2024 Oct; 26(10):1258-1270. PubMed ID: 39080202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor mutational burden in colorectal cancer: Implications for treatment.
    Marques A; Cavaco P; Torre C; Sepodes B; Rocha J
    Crit Rev Oncol Hematol; 2024 May; 197():104342. PubMed ID: 38614266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer.
    Du F; Liu Y
    J Clin Lab Anal; 2022 Jan; 36(1):e24141. PubMed ID: 34817097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
    Wang C; Fakih M
    Expert Opin Biol Ther; 2021 Oct; 21(10):1347-1357. PubMed ID: 34030532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma.
    San-Román-Gil M; Torres-Jiménez J; Pozas J; Esteban-Villarrubia J; Albarrán-Fernández V; Álvarez-Ballesteros P; Chamorro-Pérez J; Rosero-Rodríguez D; Orejana-Martín I; Martínez-Delfrade Í; Reguera-Puertas P; Fuentes-Mateos R; Ferreiro-Monteagudo R
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab for the treatment of colorectal cancer.
    Coupez D; Hulo P; Touchefeu Y; Bossard C; Bennouna J
    Expert Opin Biol Ther; 2020 Mar; 20(3):219-226. PubMed ID: 31952453
    [No Abstract]   [Full Text] [Related]  

  • 39. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 40. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.